

Neuland Laboratories Limited
11th floor (5th level), Phoenix IVY Building,
Plot No.573A-III, Road No.82, Jubilee Hills,
Hyderabad-500033, Telangana, India.



CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

December 19, 2025

To

BSE Limited

Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Newspaper advertisement regarding Special Window for re-lodgement of transfer request of physical shares

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed copies of newspaper advertisement informing about the Special Window for re-lodgement of transfer request of physical shares, as published in Financial Express and Nava Telangana on December 19, 2025.

This is for your information and records.

Thanking You,

Yours sincerely,

For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: As above

POOR FORCED TO BUY DRUGS FROM PRIVATE CHEMISTS

Respiratory medicine out of stock at top Delhi hospital as AQI peaks

ANKITA UPADHYAY
New Delhi, December 18

IN THE MIDDLE of North India's air pollution season, with outpatient numbers having risen an estimated 20% above the baseline across hospitals in the national capital, the largest hospital run by the Delhi government is running short of drugs to treat respiratory illnesses, say patients.

At Lok Nayak Hospital, where complaints of breathing problems triggered by air pollution spike every winter, essential drugs including nebuliser solutions, cough syrups, multivitamins, and several inhalers are not available, forcing patients to buy them from private pharmacies.

Pharmacy staff had crossed out several medicines or marked them as "not available" in prescriptions to OPD patients at Lok Nayak over two days this week.

Patients said they had been advised to purchase these drugs from the market.

Hospitals run by the Delhi

STARK REALITY

■ Hospitals run by the Delhi government provide medicines to patients for free

■ Many of those who visit government hospitals are poor, and find it difficult to buy medication

■ Pharmacy staff had crossed out several medicines as "not available" in Lok Nayak Hospital prescriptions

The average air quality index (AQI) in Delhi deteriorated to 373 on Thursday after having improved marginally to 334 on Wednesday



A crowded Lok Nayak Hospital pharmacy in Delhi

government provide medicines to patients for free. Many of those who visit government hospitals are poor, and find it difficult to buy their prescribed medication. The cost of a metered-dose inhaler (MDI) typically ranges from several hundred to more than a thousand rupees per unit.

A woman from Daryaganj who gave her name as Nisha said she had been told that Bromhex-

ine syrup and a multivitamin syrup prescribed for her 7-year-old son Naman were out of stock at the hospital pharmacy.

Bromhexine is commonly prescribed to thin mucus, ease coughs and relieve chest congestion in patients suffering from bronchitis.

Nisha, who said she had been visiting Lok Nayak for years, claimed that shelves had been getting increasingly empty over

the past couple of years. "Kuchh nahin milta yahaan... Hamesha baahar se leni padti hai dawai (You get nothing here, you have to buy medicines from outside)," she said.

Naman had been ill for the past two weeks, and had suffered nosebleeds on a few occasions, Nisha said. "I have no income, and my husband teaches in a nearby school. I am worried about Naman," she said.

Forty-six-year-old Prem Kumar, who works as a security guard in Mayur Vihar, said he was unable to get MDI Tiova, NAC 600 tablets, and Bromhexine, which had been prescribed for his persistent cough and breathlessness.

At Tiova inhaler, which makes breathing easier by relaxing airway muscles and widening the airways, costs ₹535. NAC 600, which is used to loosen mucus in the lungs, windpipe, and nasal passage, costs about ₹330 for 10 tablets. Other commonly prescribed drugs are more expensive – the Seroflo 250 inhaler costs about ₹914, and the Seroflo 250 Synchronbreath about ₹1,040.

The average air quality index (AQI) in Delhi deteriorated to 373 on Thursday after having improved marginally to 334 on Wednesday from 354 on Tuesday, according to Central Pollution Control Board (CPCB) data. Air quality had slipped to the 'severe' category – above 400 – on Monday, Sunday and Saturday.

No problem with Centre, except on statehood, but L-G interfering: Omar

DIVYAA
New Delhi, December 18

J&K CHIEF MINISTER Omar Abdullah has said that while the BJP-led NDA regime at the Centre was "sort of well disposed" towards his administration, except on the issue of statehood, the same did not hold true for its appointee Lieutenant Governor Manoj Sinha who was "essentially interfering" in the functioning of an "elected government".

Speaking at the Express Adda Wednesday, Abdullah also spoke about his unease in using "the words Union Territory and Jammu-Kashmir in the same sentence".

Referring to Sinha, he said, "In spite of the fact that he has on numerous occasions publicly said that he is only responsible for security, and law and order, and everything else is the domain of the elected government, that has not been translated on the ground. I can name institutions that should ordinarily have transferred to the elected government that haven't so far," he said.

Responding to questions on a range of other issues as well, Abdullah sought to make a distinction between the Opposition finding fault with voting machines, which he was not in favour of, and the functioning of the Election Commission where, he said, "We have a problem".

The National Conference leader also described as "deeply distressing" the incident last week of Bihar Chief Minister Nitish Kumar pulling the hijab from a student's face at a felicitation function.

Asked about the relationship between his government and the Centre, Abdullah said, "Other than a couple of major issues on which, obviously, we haven't made as much progress as I would have liked, particularly on



Jammu and Kashmir Chief Minister Omar Abdullah at the Express Adda in New Delhi on Wednesday

RENUKA PURI



the restoration of statehood and pending that our business rules being approved, the government of India has been sort of well disposed towards the government of Jammu & Kashmir."

While referring to the L-G, however, he pointed to how Sinha was chairman of the J&K State Power Development Corporation (JKSPDC) and Chancellor of state universities, while chairing cultural academies and convening meetings on tourism.

"I am the power minister. It (JKSPDC) is a corporation that is part of the ministry but the L-G is the chairman of that corporation, (which he

shouldn't be... I was chairman of that corporation when I was chief minister (in the previous stint)," Abdullah said.

"We have two universities (Baba Ghulam Shah Badshah University and Islamic University of Science and Technology) and their statutes meant that the chief minister was chancellor... After the elections, these universities should have been transferred to the elected government. They haven't," he said.

"He (Sinha) is chairman of the cultural academy even though the culture department is with the elected government... I am the tourism minister but he continues to hold on even to tourism development authorities... Somebody who says he is only responsible for security and law and order, what business does he have holding a tourism development authority, it is essentially interfering in the role of the elected government," Abdullah said.

However, the J&K CM said that despite his issues with the L-G, the Central government's conduct has left him "with limited scope to complain". "They gave more money to my government at the end of last year than was actually part of the budget. And I have every hope and expectation that the same thing will be done this year as well," he said.

And yet, the main issue of statehood remained "a matter of disappointment", he said.

On a personal note, Abdullah spoke about his distress at being called chief minister of the Union Territory of Jammu & Kashmir. "I find it very difficult to use the words Union Territory and Jammu-Kashmir in the same sentence. In fact, if anything I hate being reminded that we are a Union Territory," he said.

The Express Adda was moderated by Vandita Mishra, National Opinion Editor, *The Indian Express*.

Mohun Bagan suspended, fined over \$100K by AFC

REUTERS
December 18

MOHUN BAGAN SUPER Giant has been banned from Asian Football Confederation (AFC) competitions and ordered to pay more than \$100,000 (about ₹91 lakh) for refusing to travel to Iran for an Asian Champions League Two clash with Sepahan SC in September, the Asian soccer body said in a statement.

The AFC's disciplinary and ethics committee excluded Mohun Bagan from the next edition of Asian competition they qualify for, up to the 2027-28 season, in a decision made on Wednesday.

The Indian champions were also handed a \$50,000 fine and told to pay an additional \$50,729 for damages and losses incurred by the AFC and Sepahan. Mohun Bagan have also forfeited any subsidy for participating in the continental second-tier tournament.

Mohun Bagan were withdrawn from the competition after they refused to travel to Iran for the group stage match, citing lack of security assurances and medical insurance coverage in Iran, and their matches were declared null and void by the AFC.

The club had moved to the Court of Arbitration for Sport asking for the match to be re-

lated to a neutral venue, but CAS turned down their initial request.

"The players decided they can't take this risk, where lives and their families' future are at stake. So we have to stand with them," a senior Mohun Bagan official told Reuters.

Mohun Bagan have five players from Australia, Spain and the United Kingdom, countries that have advised their citizens against travelling to Iran, the official added.

The club also did not travel to Iran last year for a match against Tractor SC scheduled for October 2, 2024, the day after Iran launched ballistic missiles towards Israel.

SECURITY THREAT



■ The action is for refusing to travel to Iran for an Asian Champions League Two clash with Sepahan SC in September

■ The club refused to travel to Iran for the group stage match, citing lack of security assurances and medical insurance coverage in Iran

COVIDH TECHNOLOGIES LIMITED

Corporate Identification Number: L72200TG1993PLC015306

Registered Office: B-2, Plot: 797/A, Sai Krishna Building, Road No. 36, Jubilee Hills, Hyderabad, Telangana, India, 500033

Tel No.: 040-64643093; Fax: 040-40266738

Website: www.covidhtechnologies.com; Email: cscovidh@gmail.com, info@covidh.com

Recommendations of the Committee of Independent Directors ("IDC") of COVIDH TECHNOLOGIES LIMITED ("CTL" or "Target Company") on the Offer made by Mr. Pratap Deshmukh ("Acquirer 1"), Mr. Laulik Deshmukh ("Acquirer 2"), Ms. Sharmila Deshmukh ("Acquirer 3"), Ms. Shubhangi Garad ("Acquirer 4"), Mr. Sumeet Garad ("Acquirer 5"), Ms. Ritu Garad ("Acquirer 6"), Mr. Dhairyaashel Yadav ("Acquirer 7"), Mr. Nandakumar Kadam ("Acquirer 8"), Ms. Archana Lonkar ("Acquirer 9") (hereinafter referred to as "Acquirers") to the Shareholders of the Target Company under Regulation 26(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 including subsequent amendments thereto ("SEBI (SAST) Regulations").

1. Date	Thursday, December 18, 2025
2. Name of the Target Company	Covidh Technologies Limited
3. Details of the Offer pertaining to the Target Company	This Offer is being made by Mr. Pratap Deshmukh ("Acquirer 1"), Mr. Laulik Deshmukh ("Acquirer 2"), Ms. Sharmila Deshmukh ("Acquirer 3"), Ms. Shubhangi Garad ("Acquirer 4"), Mr. Sumeet Garad ("Acquirer 5"), Ms. Ritu Garad ("Acquirer 6"), Mr. Dhairyaashel Yadav ("Acquirer 7"), Mr. Nandakumar Kadam ("Acquirer 8") and Ms. Archana Lonkar ("Acquirer 9") pursuant to the provisions of Regulations 3 and 4 of the SEBI (SAST) Regulations, for acquisition of upto 21,86,333 (Twenty One Lakh Eighty Six Thousand Three Hundred and Thirty Three Only) Equity Shares of ₹ 10/- each representing 26.00% of the Emerging Equity and Voting Share Capital of the Target Company, at a price of ₹ 10.00 (Rupees Ten Only) per Equity Share, payable in cash.
4. Name of the Acquirer	Mr. Pratap Deshmukh ("Acquirer 1"), Mr. Laulik Deshmukh ("Acquirer 2"), Ms. Sharmila Deshmukh ("Acquirer 3"), Ms. Shubhangi Garad ("Acquirer 4"), Mr. Sumeet Garad ("Acquirer 5"), Ms. Ritu Garad ("Acquirer 6"), Mr. Dhairyaashel Yadav ("Acquirer 7"), Mr. Nandakumar Kadam ("Acquirer 8") and Ms. Archana Lonkar ("Acquirer 9")
5. Name of the Manager to the Offer	Bonanza Portfolio Limited CIN: U65991DL1993PLC052280 Bonanza House, Plot No. M-2, Cama Industrial Estate, Walbhai Road, Behind The Hub, Goregaon (East), Mumbai - 400 063
6. Members of the Committee of Independent Directors	1. Mr. Rinku Saini, Chairperson 2. Mangina Srinivas Rao, Member
7. IDC Member's relationship with the Target Company (Directors, Equity Shares owned, any other contract/relationship), if any	a) IDC members are Independent and Non-Executive Directors on the Board of the Target Company. b) None of the IDC member holds Equity Shares in the Target Company. c) None of the IDC member holds any contract or relationship with the Target Company at present.
8. Trading in the Equity Shares/ other securities of the Target Company by IDC Members	None of the IDC members have traded any Equity Shares/ other securities of the Target Company during a period of 12 months prior to the date of Public Announcement till the date of this recommendation.
9. IDC Member's relationship with the Acquirer (Directors, Equity Shares owned, any other contract/relationship)	None of the IDC members have any relationship with the Acquirer at present.
10. Trading in the Equity Shares/ other securities of the Acquirer by IDC Members	Nil
11. Recommendation on the Offer, as to whether the Offer, is or is not, fair, and reasonable	The IDC members have reviewed the following documents issued by the Manager on behalf of the Acquirer (collectively referred to as the "Offer Documents"): (a) the Public Announcement dated Friday, October 03, 2025; (b) the Detailed Public Statement published in newspaper on Friday, October 10, 2025; (c) the Draft Letter of Offer dated Friday, October 17, 2025; and (d) the Letter of Offer dated Tuesday December 15, 2025. The IDC members believe that Offer is fair and reasonable, in accordance with the provisions of SEBI (SAST) Regulations.
12. Summary of Reasons of Recommendation	Based on the review of the Offer Documents, the IDC members are of the opinion that the Offer Price of ₹ 10 per Equity Shares, offered by the Acquirers is in line with Regulation 8(2) of SEBI (SAST) Regulations and prima facie appears to be justified. The Committee considered the following facts: a) The Equity Shares of the Company are infrequently traded on BSE within the meaning of Regulation 2(1)(i) of SEBI (SAST) Regulations; b) The Offer Price of ₹ 10 per Equity Shares is justified in terms of the parameters prescribed under Regulations 8(2) of the SEBI (SAST) Regulations. Keeping in view of the above fact, the IDC members are of the opinion that the Offer Price of ₹ 10 (Rupees Ten Only) payable in cash per Equity Share to the Shareholders of the Target Company for this Offer is fair and reasonable. However, the Shareholders should independently evaluate the Offer and take informed decision on the matter.
13. Details of Independent Advisors, if any	Nil
14. Disclosure of Voting Pattern of the meeting in which the open offer proposal was discussed	The recommendations were unanimously approved by the members of the IDC.
15. Any other matter to be highlighted	Nil

To the best of our knowledge and belief, after making proper enquiry, the information contained in or accompanying this statement is, in all material respect, true, correct, and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by the Target Company under SEBI (SAST) Regulations.

For and on behalf of
Committee of Independent Directors
Covidh Technologies Limited
Sd/-
Rinku Saini
(Chairperson of IDC)

Place: Mumbai
Date: December 18, 2025

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Registered office: 11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-III, Road No. 82, Jubilee Hills, Hyderabad, 500033, Telangana, India.
Tel: 040 6761 1600, ir@neulandlabs.com, www.neulandlabs.com

NOTICE TO SHAREHOLDERS

SPECIAL WINDOW FOR RE-LODGE OF TRANSFER REQUEST OF PHYSICAL SHARES

Notice is hereby given that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025, has decided to open a Special Window only for re-lodgement of transfer deeds which were lodged prior to April 1, 2019 and rejected / returned / not attended, due to deficiency in the documents / process / or otherwise and could not be lodged upto March 31, 2021. The special window shall remain open for a period of six months from July 7, 2025 till January 6, 2026.

During this special window period, re-lodgement of legally valid and complete documents for transfer of physical shares (including those requests that are pending with the listed company/RTA as on date) will be considered and the shares that are re-lodged for transfer shall be issued only in demat mode after following the due process prescribed by SEBI.

Eligible Shareholders may submit their transfer requests along with requisite documents within the stipulated period to the Company's Registrar and Share Transfer Agent (RTA) KFin Technologies Limited at their office at Selenium Building, Tower-B, Plot No. 31 & 32, Financial District Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana, India – 500 032, or write an at email einward.ris@kfinetech.com.

By Order of the Board
For Neuland Laboratories Limited
Sd/-
Sarada Bhamidipati
Company Secretary

Place: Hyderabad
Date: December 18, 2025

NAVI MUMBAI INTERNATIONAL AIRPORT

NOTICE INVITING EXPRESSION OF INTEREST FOR SITC OF VARIOUS TYPES OF RADIOACTIVE DETECTION EQUIPMENT (RDE) AT NMIA

Navi Mumbai International Airport Private Limited ("NMIAL") has been granted the right to develop, operate and maintain the Navi Mumbai International Airport ("NMIA") on DBFOT basis. As a part of project development at NMIA, NMIAL proposes to undertake the award of various types of Radioactive Detection Equipment (RDE) Tender.

The scope of works for each of the above work includes but will not be limited to Supply, installation, integration, interfacing, testing, commissioning, operation trials, obtaining all requisite statutory approvals / licenses, warranty support, rectification of defects, obligations during Warranty Period/ defect rectification period, supply of spares and special tools, providing labour, material, equipment and services of Radioactive Detection Equipment (RDE) and shall include all works including related, associated and temporary works as may be required."

NMIAL invites responses to the Expression of Interest ("EOI") from qualified, experienced and reputed contractors in each of these categories.

Interested applicants may download and submit their response to the EOI by registering on the NMIAL e-tender portal: <https://nmiairport.abcpurchase.com> Applicants are required to submit the response under the corresponding Event IDs, depending upon the category they chose to apply for. For further details and instructions, please visit the E-tenders section of our website: www.nmiairport.co.in.

The deadline for submission of the response to EOI is **30th December 2025, 15:00 hrs IST**.

Note: NMIAL reserves the right to reject any response to EOI or change / cancel the tender process at any time without prior notice or without assigning any reason whatsoever.

NAVI MUMBAI INTERNATIONAL AIRPORT PVT. LTD.
Email: nmiai.tenders2@adani.com
Website: www.nmiairport.co.in

HDFC

MUTUAL FUND

BHAROSA APNO KA

HDFC Asset Management Company Limited

CIN: L65991MH1999PLC123027

Registered Office: HDFC House, 2nd Floor, H.T. Parekh Marg, 165-166, Backbay Reclamation, Churchgate, Mumbai - 400 020. Phone: 022 66316333 • Toll Free Nos: 1800-3010-6767 / 1800-419-7676
e-mail: hello@hdfcfund.com • Visit us at: www.hdfcfund.com

NOTICE

NOTICE is hereby given that HDFC Trustee Company Limited, Trustee to HDFC Mutual Fund ("the Fund"), has approved the following distribution under Income Distribution cum Capital Withdrawal ("IDCW") Option of **HDFC Arbitrage Fund**, an Open-ended Scheme investing in Arbitrage Opportunities ("the Scheme") and fixed **Tuesday, December 23, 2025** (or the immediately following Business Day, if that day is not a Business Day) as the Record Date for the same:

Name of the Scheme / Plan(s) / Option(s)	Amount of Distribution (₹ per unit)#	Face Value (₹ per unit)	Net Asset Value ("NAV") as on December 17, 2025 (₹ per unit)
HDFC Arbitrage Fund - Wholesale Plan - Regular Plan - Normal IDCW Option (Payout and Reinvestment)			10.941
HDFC Arbitrage Fund - Wholesale Plan - Direct Plan - Normal IDCW Option (Payout and Reinvestment)			11.654
HDFC Arbitrage Fund - Wholesale Plan - Regular Plan - Monthly IDCW Option (Payout and Reinvestment)	0.050	10.00	11.398
HDFC Arbitrage Fund - Wholesale Plan - Direct Plan - Monthly IDCW Option (Payout and Reinvestment)			11.264

#Amount of distribution per unit will be the lower of that mentioned above or the available distributable surplus (rounded down to a multiple of five at the third decimal) as on the Record Date.

Pursuant to the Distribution, the NAV of the IDCW Option(s) of the above Scheme would fall to the extent of such distribution and statutory levy, if any.

Amount will be paid, net of applicable tax deducted at source (TDS), to those Unit holders / Beneficial Owners whose names appear in the Register of Unit holders maintained by the Fund / Statements of Beneficial Ownership maintained by the Depositories, as applicable, under the IDCW Option(s) of the aforesaid Scheme on the Record Date (including investors whose valid purchase / switch-in requests are received by the Fund and the funds are available for utilization before cut-off timings in respect of the aforesaid Scheme, on the Record date).

With regard to Unit holders who have opted for Reinvestment facility under the IDCW Option(s), the amount due (net of applicable TDS) will be reinvested, by allotting Units at the applicable NAV per Unit (adjusted for applicable stamp duty).

As mandated under SEBI (Mutual Funds) Regulations and Master circular for Mutual Funds dated June 27, 2024, for redemptions and IDCW declared, payout will be done only through electronic mode(s), even where a Unit holder has opted to receive physical instruments. Thus, payment of such amounts shall be made through physical instruments, only in exceptional circumstances for reasons to be recorded by the AMC. Accordingly, unit holders who have opted for / have earlier received physical instruments are requested to update their bank account details by / sending us a copy of a cancelled cheque of first / sole holder's bank account.

All updates of PAN, KYC, email address, mobile number, nominee details, etc. should immediately be forwarded to the Investor Services Centers of the Fund (for units held in non-demat form) / Depository Participant (for units held in demat form). Unit holders are also advised to link their PAN with Aadhaar Number. Further, Unit holders can view the Investor Charter available on website of the Fund as well as check for any unclaimed redemptions or IDCW payments.

In view of individual nature of tax consequences, each investor should seek appropriate advice.

For HDFC Asset Management Company Limited
(Investment Manager to HDFC Mutual Fund)

Place : Mumbai
Date : December 18, 2025

Sd/-
Authorized Signatory

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.

